RecruitingNot Applicable

DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

United States900 participantsStarted 2025-01-23

Plain-language summary

This is a prospective, real world, multicenter, registry of patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD) and interstitial lung disease (ILD).

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Adults aged 18 years or older
✓. Diagnosis of fibrotic ILD based on high-resolution computed tomography imaging, including but not limited to:
✓. Idiopathic interstitial pneumonia, including idiopathic pulmonary fibrosis
✓. Autoimmune ILD
✓. Chronic hypersensitivity pneumonitis
✓. Nonspecific interstitial pneumonia
✓. Occupational lung disease
✓. Combined pulmonary fibrosis and emphysema with fibrosis greater than the extent of emphysema on lung imaging as determined by the Investigator

Exclusion criteria

✕. Confirmed diagnosis of Group 1, 2, 4, or 5 PH
✕. Confirmed diagnosis of Group 3 PH associated with lung diseases and or hypoxia other than fibrotic ILD, as outlined in Inclusion Criterion 2.
✕. Patients receiving inhaled treprostinil (Yutrepia™) at Baseline. Patients receiving other forms of PH therapy will be eligible for enrollment.

What they're measuring

Baseline characteristics as described by demographics, medical history, ILD history, PH history, family history (comorbidities), and diagnostic right heart catheterization values.

Timeframe: Baseline

Trial details

NCT IDNCT06388421

SponsorUnited Therapeutics

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2030-09-01

Contact for this trial

United Therapeutics Global Medical Information

919-485-8350 clinicaltrials@unither.com

View on ClinicalTrials.gov More Pulmonary Hypertension Due to Lung Diseases and Hypoxia trials